skip to Main Content

About

Management Team

Allen Baharaff
President and Chief Executive Officer

Mr. Baharaff is the co-founder of Galmed Pharmaceuticals Ltd., and has served as CEO since 2012, and President as of 2015. Since its inception in 2000, Mr. Baharaff served as CFO since 2000. He holds a Bachelor of Science degree from the University of London (LSE) and LLB and MA degrees from Cambridge University. Mr. Baharaff has held a number of directorships including a SVP position at Isramex Projects Ltd., and T+M Trusteeship & Management. He also serves as a Director of the Tel-Aviv Museum of Arts, chairing the committee for educational activities.

Josh Blacher
Chief Financial Officer

Mr. Blacher joined Galmed in 2014 with six years of experience in biotech-related business development, investing and operations, as well as 14 years in capital markets. Prior to joining Galmed, Mr. Blacher served as Director of Business Development at Teva Innovative Ventures, Teva Pharmaceuticals’ early- and mid-stage investment and in-licensing arm. In that capacity, Mr. Blacher helped build and manage Teva’s portfolio of approximately 20 equity investments in biotech companies, spanning a wide range of development stage companies from pre-clinical through Phase III projects, as well as various therapeutic areas. Previously, Mr. Blacher also held positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.

Dr. Liat Hayardeny
Chief Scientific Officer

Dr. Hayardeny joined Galmed in September 2016 bringing more than 16 years of experience in drug development as part of Teva Pharmaceuticals’ global R&D Division. Prior to joining Galmed, Dr. Hayardeny served as Teva’s Senior Director and Head of Research Scientific Affairs. In that capacity, Dr. Hayardeny established the scientific positioning of Teva’s innovative compounds. Additionally, Dr. Hayardeny was responsible for the company’s relationship with institutions of higher education; managing Teva’s global research collaborations and publications. Dr. Hayardeny holds a Ph.D. from Sackler School of Medicine and an MBA from Recanati Business School at Tel Aviv University.

Professor Ran Oren, M.D.
Chief Medical Officer

Professor Ran Oren, MD, joined Galmed as Chief Medical Officer in mid-2016. Dr. Oren is also Professor of Gastroenterology & Hepatology at the Faculty of Medicine, Hebrew University of Jerusalem, Israel, and is the Head of the Institute of Gastroenterology and Liver Disease at Hadassah Medical Center, Jerusalem, Israel. Dr. Oren has received numerous academic and professional awards in his field and holds several patents related to the prevention and arresting of human liver disease. Additionally, in 2000, Dr. Oren established the Liver Unit at the Tel Aviv Sourasky Medical Center, where he served as Chief of Medicine from 2008 to 2010. Dr. Oren concurrently served as the President of the Israeli Association for the Study of the Liver between 2007 and 2010.

George Tonelli
Vice President, Clinical Operations

Mr. Tonelli joined Galmed in March, 2015, bringing 24 years of progressive experience in clinical development, operations and regulatory affairs. From 2005-2014, he planned and managed diabetes trials at MannKind Corporation, culminating in FDA approval of Afrezza® Inhalable Insulin. Prior to MannKind he held leadership positions in clinical development and project management at Innapharma. He began his career in regulatory affairs in the Medical Research Division of American Cyanamid (Lederle Labs). Mr. Tonelli holds a Bachelor of Science degree from Rutgers University.

Dr. Antony Appleyard
Vice President, Drug Development

Dr. Appleyard joined Galmed in 2012 with over 15 years of experience in R&D, formulation, and manufacturing. Previously, Dr. Appleyard was an Associate Director of Natural Products Chemistry at Novacta Biosystems, and at Cantab Biopharmaceutical, where he also headed the companies’ CMC and analytics efforts. From 2003 to 2004, Dr. Appleyard was engaged in international technology transfer activities for MAb processes at Abbott Laboratories. Dr. Appleyard also serves as a senior consultant at Diamond BioPharm, where he provides product development, regulatory and project management services. He was awarded a degree in chemistry with honors in 1995 and a Ph.D. in biochemistry in 2001, both from the University of Leeds. From 2001 to 2003, Dr. Appleyard conducted postdoctoral research in the Departments of Chemistry and Biochemistry at the University of Cambridge. He is a Fellow of The Royal Society of Chemistry and a Chartered Chemist.

Back To Top